Introduction
Infection with respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and hospitalization in infants between 1 and 6 months of age (Collins et al., 1996) and RSV disease can also be severe in the elderly and immunocompromised. Efforts to develop a vaccine for RSV have been hampered by the results of early studies showing that formalininactivated RSV vaccine caused an abnormal and pathological immune response upon subsequent exposure to RSV (Kim et al., 1969) . It is therefore important to develop a vaccine that can overcome this and epitope-based vaccines represent one possible approach (Blaney et al., 1998 ; Hsu et al., 1998 Hsu et al., , 1999 .
Studies in the mouse model of RSV have demonstrated that both CD4 + and CD8 + T cells are crucial for the termination of the primary infection but that these cells may also be pathogenic (Graham et al., 1991) . The vaccine-enhanced illness is thought to have resulted from an inappropriate immune response leading to an excess of TH2-type cytokines, particularly IL-4 and IL-5, and an influx of eosinophils (Connors et al., 1994 ; Waris et al., 1997 ; Graham, 1996) . The attachment glycoprotein (G) of RSV has been implicated Hsu et al., 1999) . Furthermore, although CTL are likely to be important in both recovery and protection from RSV, the G protein does not induce detectable CTL responses (Bangham et al., 1986 ; Srikiatkhachorn et al., 1997) . In contrast, the fusion protein (F) of RSV induces a TH1-type cytokine response and the development of CD8 + CTL (Bangham et al., 1986; Alwan et al., 1993) while immunization of CD8-deficient mice or mice depleted of CD8 + T cells with the F protein led to a TH2 response and eosinophilia (Srikiatkhachorn & Braciale, 1997) . Thus, to avoid immunopathology, it is necessary to design vaccines that promote CD8 + T cell responses : the F protein, a major target of CTL isolated during primary RSV infection in mice (Alwan et al., 1993 ; Kulkarni et al., 1993) and humans (Cherrie et al., 1992) , is a likely candidate.
In this study we describe a peptide from the F protein of RSV that behaves as an allele-specific CTL epitope in BALB\c mice (H-2 d ). Despite being motif-negative, this peptide was not only recognized by RSV-specific CTL but, following immunization, generated virus-specific CTL responses which S. Jiang and others S. Jiang and others significantly reduced the viral load in the lungs following challenge with RSV.
Methods
Peptides. Peptide synthesis was performed by the RAMPS (Rapid Multiple Peptide Synthesis ; Dupont) method using Fmoc chemistry with the Rink Amide MBHA resin (C N Biosciences UK, Beeston, Notts). The purity of the peptides was assessed by reverse-phase HPLC and by mass spectrometry (Eurogentec). All peptides were greater than 85 % pure and had their expected mass. The CTL epitope M2-9 (ESYIGSINNITKQSA) from the M2 protein of RSV (Kulkarni et al., 1993) and a chimeric peptide representing the F peptide from the fusion protein of measles virus and the M2-9 epitope (F\M2-9) (Hsu et al., 1999) were used as the positive control epitopes for the CTL assays. The T helper epitope SH45-60 (CEYNVFHNKTFELPRA) from the SH protein of RSV (Kulkarni et al., 1993) was used as a positive control epitope for lymphocyte proliferation assays. Peptide 8 and the overlapping 9-, 10-, 11-, 12-, 13-and 14-mer peptides from its sequence were synthesized using a 9050 Peptide Synthesizer (Applied Biosystems) and purified by reverse-phase HPLC to greater than 95 % purity.
H-2K
d : β 2 -microglobulin : peptide P8 : F92-106 complex assembly. Constructs encoding amino acids 1-280 of the heavy chain of H-2K d and amino acids 1-99 of β # -microglobulin were cloned and expressed in the T7 promoter-based vector pGMT7 in E. coli (Gao et al., 2000) and inclusion bodies of both K d and β # -microglobulin were prepared. Complex refolding with or without peptide P8 : F92-106 was carried out by dilution in a redox buffer in a standard MHC class I refolding assay (Garboczi et al., 1992) . The MHC-peptide complex formed was separated by gel filtration on a Superdex 200 column (Amersham Pharmacia) and the eluted peaks analysed by SDS-PAGE.
RSV and cell lines. The A2 strain of RSV was grown and titrated on Hep-2C cells as previously described (Hsu et al., 1999 Mice and immunization. Mice, BALB\c (H-2 d ), C57BL\6 (H-2 b ) and CBA (H-2 k ) mice (NIMR, Mill Hill, UK) and BALB\c CB-17 scid mice (LSHTM, London) were either infected intranasally (i.n.) with RSV (10' p.f.u.\100 µl\mouse) or immunized subcutaneously (s.c.) with 100 µg peptide in complete Freund's adjuvant (Difco) followed 3 weeks later by a booster of peptide in incomplete Freund's adjuvant (Difco). For lymphocyte proliferation assays, mice were immunized s.c. with P8 : F92-106 or with SH45-60 twice at weekly intervals, and the spleens removed 1 week after the second immunization.
Pulmonary and splenic CTL assays. To measure primary CTL responses in the lung, mice were infected i.n. with 10' p.f.u. RSV in 100 µl. Lungs were removed after 7 days and homogenized in cold DMEM-5 (Life Technologies). Lymphocytes were isolated by gradient centrifugation on Histopaque-1083 (Sigma) and cultured in RPMI 1640 (Life Technologies) containing 10 % FCS, 10 mM HEPES (Life Technologies), 50 µM 2-mercaptoethanol (Sigma) and antibiotics at the required concentration as effectors. For the splenic CTL assays, splenic mononuclear cells were isolated from immunized mice and restimulated in vitro with 0n5 M peptide for 6-7 days.
Target cells for the CTL assays were BALB\c fibroblasts and BCH4 cells. These were labelled with &"Cr (200 µCi\2i10( cells ; Amersham Pharmacia). Targets were pulsed with 10 µM peptides for 1 h at 37 mC. Titration experiments confirmed this to be the optimal concentration of peptide for these experiments. &"Cr-labelled non-peptide-pulsed BALB\c fibroblasts were used as a control. In the experiments with C57BL\6 mice, the target cells were C57BL\6 fibroblasts either pulsed with peptides or infected with RSV 12 h before the experiment. In the experiments with CBA mice, L929 cells were used as targets. Effectors and targets were cocultured for 6 h in a standard chromium release assay (Hsu et al., 1999) . In all experiments shown, the spontaneous release of &"Cr from target cells incubated alone was less than 20 % of the total release from target cells lysed with Triton X-100. All the assays were repeated at least twice and the data presented are representative of repeated assays.
In some experiments, effector cells were incubated with 10 µg\ml of either anti-CD8 or anti-CD4 monoclonal antibodies prior to the assay. For experiments using enzyme inhibitors, &"Cr-labelled target cells (10') were incubated for 1 h with either 10 µM lactacystin (ICN Pharmaceuticals) or with 20 or 30 µl of a protease inhibitor cocktail containing a mixture of inhibitors for the inhibition of serine, cysteine and aspartic proteases (Sigma ; cat. no. P8340). The cytotoxicity assay was performed as described above. Effectors were splenocytes from P8 : F92-106-immunized BALB\c mice.
Lymphocyte purification and flow cytometric analysis. Adherent cells were removed by plastic adherence. B cells and contaminating macrophages were depleted using anti-MHC class II antibody (clone T1B 120) followed by addition of rabbit anti-rat immunoglobulin-coated Dynabeads (Dynal). The T cells were further depleted of either CD4 + or CD8 + subsets using anti-CD4 (clone YTS 191.1 ; a gift from X. Xu, Institute of Molecular Medicine, Oxford, UK) or anti-CD8 (clone 53-6.7, BD Biosciences, Cowley, Oxford, UK), respectively followed by rabbit anti-rat Ig-coated Dynabeads as before. The enriched CD4 + and CD8 + subsets were analysed for purity by flow cytometry.
Lymphocyte proliferation assay. Splenic lymphocytes were isolated and cultured at 2i10'\ml in RPMI 1640 plus 10 % FCS plus antibiotics in the presence of peptide (12n5-0 µg\ml) for 5 days. Six hours before harvesting, cells were pulsed-labelled with 1 µCi per well of ELISA. These assays were performed as previously described (Hsu et al., 1999) . Briefly, 96-well microplates were coated with 50 µl peptide P8 : F92-106 or P18 : F192-206 at 5 µg\ml or with 50 µl RSV at 5 µg\ml. Sera from mice immunized with P8 : F92-106 or control peptide P18 : F192-206 or with RSV were added at 1 : 200. Peroxidase-conjugated anti-mouse Ig (H and L chains, Nordic Immunological Laboratories) was added and 0n04 % O-phenylenediamine\0n004 % hydrogen peroxidase (Sigma) used as the substrate and the absorbance at 490 nm measured. RSV neutralization titres were assessed as previously described (Hsu et al., 1999) . The neutralizing antibody titre was determined as the reciprocal of the highest dilution of antiserum which reduced the number of plaques by 50 % of the mean value observed in control wells containing serum from unimmunized mice.
Challenge experiments. Groups of four BALB\c mice were immunized s.c. with peptides on day 0 and day 21 and were challenged i.n. with 10' p.f.u.\100 µl RSV 3 weeks after the second immunization. Four days after challenge, the lungs were removed, weighed and homogenized. Supernatants were assayed immediately for RSV, expressed as log "! p.f.u.\g lung. For passive transfer experiments spleno-Motif-negative CTL epitope from RSV fusion protein Motif-negative CTL epitope from RSV fusion protein cytes from P8 : F92-106-primed BALB\c mice were restimulated with P8 : F92-106 in vitro for 7 days, separated into three populations -CD8 + enriched, CD4 + enriched and CD8 + plus CD4 + enriched -and transfused 10'\mouse) into three groups of five BALB\c scid mice. A fourth group was reconstituted with CD4 + and CD8 + T cells from naı$ ve animals. All four groups of mice and untreated mice were challenged i.n. with RSV 2 days after passive transfer of the lymphocytes. Four days later, all mice were killed and lungs removed for assessment of virus load. Means were compared using Student's t-test.
Results

Identification of CTL epitopes within the F protein
The amino acid sequence of the fusion protein of RSV A2 is shown in Fig. 1 (Collins et al., 1984) , where residues 1-21 represent the signal sequence. Starting from the 22nd residue, 55 peptides (15-mers) were synthesized, with the exception of peptide 55 which was 13 amino acids long. Each peptide overlapped the previous sequence by five residues. CTL isolated from the lungs of RSV-infected BALB\c mice were used as effector cells to screen the F protein peptides in a standard chromium release assay using BALB\c fibroblasts as targets. Initially, the peptides were split into eleven groups of five sequentially overlapping peptides. A previously described CTL epitope from the M2 protein of RSV, M2-9 (Kulkarni et al., 1993) , was used as a positive control, with non-pulsed BALB\c fibroblasts as a negative control. In some experiments, BCH4 cells (persistently infected with RSV) were also used. Target cells pulsed with peptides 6-10 (Fig. 2a) or with peptides 51-55 (Fig. 2b) were both efficiently killed by the RSV-specific CTL from the lung, indicating that these two groups were likely to contain one or more epitopes recognized by the CTL. Each of the peptides within groups 6-10 and 51-55 were then tested individually for CTL recognition. Only one of the peptides in group 6-10, peptide P8 : F92-106, induced high levels of lysis (Fig. 3a) , while in group 51-55 no single peptide gave significant CTL killing (Fig. 3b) . (Collins et al., 1984) . The numbered and underlined sequences represent the overlapping peptides used in this study. 
Characterization of P8 : F92-106
Peptides presented by MHC class I molecules are derived from intracellular proteins that are digested by the proteasome and transported across the endoplasmic reticulum for as-EDB S. Jiang and others S. Jiang and others 
* Lung CTL from BALB\c mice challenged with RSV 7 days earlier.
† Splenic CTL from BALB\c mice immunized with P8 : F92-106, and re-stimulated in vitro with P8 : F92-106 in the presence of IL-2. MQSTPPTNNR P8-9-1 (92-100) ELQLLMQST P8-9-2 (93-101) LQLLMQSTP P8-9-3 (94-102) QLLMQSTPP P8-9-4 (95-103) LLMQSTPPT P8-9-5 (96-104) LMQSTPPTN P8-9-6 (97-105) MQSTPPTNN P8-9-7 (98-06) QSTPPTNNR sociation with MHC class I. The majority of MHC class Iassociated peptides are 8-11 amino acids long. In addition, using predictive algorithms it is possible to identify peptide motifs that are likely to bind with high affinity to certain class I alleles and might therefore be assumed to be likely epitopes for CD8 + CTL. Peptide P8 : F92-106 is an unusual candidate for a CTL epitope, firstly because it is a 15-mer and secondly because it does not contain a motif predicted to bind to H-2 d class I molecules (Engelhard, 1994) . To confirm the MHC restriction of P8 : F92-106, a panel of cell lines was pulsed with P8 : F92-106 and used as targets in the CTL assay (Table 1) . The results show that only P8 : F92-106-pulsed cell lines expressing K d molecules (BALB\c fibroblasts and Lkd cells) were capable of effectively presenting the peptide for recognition and lysis by RSV and P8 : F92-106-specific BALB\c CTL. To ensure that the peptide was not undergoing proteolysis due to cell surface or media protease activity target cells were pulsed in the presence of a cocktail of protease inhibitors. There was a small, but significant, enhancement in the cytotoxic activity of the P8 : F92-106-primed splenocytes against protease inhibitor-treated targets at two inhibitor concentrations (Fig. 4a) . This indicates that media or cell surface protease activity may well trim the peptide but this interferes with its presentation. As a further control to ensure there was no internal processing of P8 : F92-106, target cells were pulsed in the presence of lactacystin, a proteasome inhibitor (Fig. 4b) . The cytotoxic activity of P8 : F92-106-primed splenocytes against lactacystin-treated target cells was not significantly different to that seen with untreated target cells, indicating that the proteasome is not involved. To confirm that all 15 amino acids in P8 : F92-106 are required for efficient recognition by CTL, a series of overlapping 9-15-mer peptides representing the sequence of P8 : F92-106 was synthesized and tested for the ability to serve as targets. However, only the original 15-mer sequence induced lysis by RSV-specific CTL (Table 2 ). These data strongly suggest that the full-length 15-mer P8 : F92-106 is required for recognition by CTL.
EDC
Phenotype of the RSV-specific CTL against P8 : F92-106-pulsed target cells
To confirm that the P8 : F92-106-specific effector cells recovered from the lungs of RSV-infected mice were class I restricted CD8 + CTL, the CTL assays were performed in the presence of blocking monoclonal antibodies to either CD4 or CD8. The untreated lung lymphocytes showed high levels of killing that were reduced by treatment with either anti-CD4 or anti-CD8 antibodies (lysis at an E : T ratio of 100 : 1 in duplicate experiments : Untreated : 72n8, 72n0 % ; anti-CD8 treated : 13n4, 10n1 % ; anti-CD4 treated : 37n9, 30n6 %). The significant reduction in CTL activity seen in anti-CD8-treated cells indicated these to be an important effector phenotype.
K d heavy chain : β 2 -microglobulin : peptide complex formation
In vitro refolding experiments with K d heavy chain and β # -microglobulin showed that in the presence of P8 : F92-106, a complex of approximately 43 kDa was formed as assessed by Superdex 200 chromatography (Fig. 5a ). This complex was shown by SDS-PAGE analysis to contain both K d heavy chain and β # -microglobulin (Fig. 5b) . In contrast, there was no specific complex peak observed without peptide (data not shown). This indicates that the peptide is specific for K d .
Response of BALB/c mice to immunization with P8 : F92-106
To determine if immunization with P8 : F92-106 alone could induce a CTL response, BALB\c mice were immunized with P8 : F92-106, M2-9 (positive control) or P18 : F192-206 (negative control). Splenocytes were re-stimulated in vitro with the same peptides for 7 days and assayed for CTL activity. P8 : F92-106-primed BALB\c lymphocytes lysed not only P8 : F92-106-pulsed target cells but also the persistently RSVinfected cell line BCH4, but did not lyse cells pulsed with an irrelevant peptide (Fig. 6a) . The level of lysis of BCH4 by P8 : F92-106-specific CTL was similar to that seen with the CTL induced by immunization with the M2-9 peptide (Fig.  6b ). Mice immunized with an irrelevant peptide, P18 : F192-206, had no demonstrable CTL activity against BCH4, or P8 : F92-106-pulsed targets (data not shown). To investigate the phenotype of the effector cells, splenocytes from P8 : F92-106-immunized BALB\c mice were separated into CD4 + -and CD8 + -enriched populations and used as effectors in a CTL assay against either RSV-infected BCH4 cells or peptide P8 : F92-106-pulsed BALB\c fibroblasts. The results clearly show that the majority of the CTL activity observed was present in the CD8 + T cell subset (Fig. 6c) , indicating that the peptide promotes the differentiation of classical CD8 + , MHC class I-restricted CTL.
Splenocytes from groups of C57BL\6 (H-2 b ) and CBA (H-2 k ) mice immunized with P8 : F92-106 had no CTL activity against either P8 : F92-106-pulsed or RSV-infected C57BL\6 fibroblasts or L929 target cells, respectively. Furthermore, splenocytes from P8 : F92-106-immunized C57BL\6 and CBA mice had no demonstrable CTL activity against P8 : F92-106-pulsed targets or against RSV-infected BCH4 cells (data not shown), further suggesting that P8 : F92-106 is restricted to H-2 d .
Immunization of mice with peptide P8 : F92-106 was also able to prime lymphocytes for a dose-dependent proliferative EDE Motif-negative CTL epitope from RSV fusion protein Motif-negative CTL epitope from RSV fusion protein response upon subsequent restimulation in vitro (data not shown). The levels of proliferation seen were similar to those induced by the positive control, peptide SH-45, an H-2 d T helper cell epitope from the SH protein of RSV (Kulkarni et al., 1993) . In ELISA, immune serum from P8 : F92-106-immunized mice was able to recognize P8 : F92-106 but not RSV (A %*! at 1\200 dilution of sera : P8 : F92-106 2n00 0n11, RSV 0n16 0n03, P18 : F192-206 0n20 0n01). These anti-P8 : F92-106 antibodies were, however, unable to neutralize RSV in vitro (neutralizing titre, log # anti-RSV 6n5 2n0, anti-P8 : F92-106 0n7 0n05, anti-P18 : F192-206 0n6 0n04). Thus, although immunization with P8 : F92-106 induced peptide-specific antibodies, it is very unlikely that this peptide represents an important protective B cell epitope.
Effect of P8 : F92-106 immunization on virus recovery following challenge with RSV
To investigate if immunization with P8 : F92-106 could reduce viral load following infection with RSV, groups of mice were immunized with either P8 : F92-106, F\M2-9, P18 : F192-206 or with adjuvant only and then challenged with RSV. Titres from mice immunized with P8 : F92-106 and the positive control F\M2-9 were 630 and 160 p.f.u.\g respectively, near the limit of detection of the assay (10# p.f.u.\g tissue). These were both significantly lower than those recovered from control, adjuvant only immunized mice (12 500 p.f.u.\g) or P18 : F192-206-immunized mice (4000 p.f.u.\g; P 0n001 ; Fig. 7a) . Thus, immunization with P8 : F92-106 can significantly reduce virus titres in the lung following RSV challenge.
To confirm the role of CD8 + T cells as the effector cells responsible for the decrease in viral load, splenocytes from EDF P8 : F92-106-immunized mice were purified by negative depletion into three populations : CD4 + T cells, CD8 + T cells and CD4 + plus CD8 + T cells. These cell populations were transferred into BALB\c scid mice : 10' cells were transferred into each mouse and, as a control, 10' T cells isolated from naı$ ve animals were transferred into a fourth group of animals. Two days after transfer, the mice were challenged i.n. with RSV. The lungs were removed 4 days later and the RSV titre measured by plaque assay. Both the unreconstituted scid mice and those animals receiving T cells from naı$ ve mice showed similar high titres of RSV in their lungs (Fig. 7b) . However, the passive transfer of CD4 + plus CD8 + T cells and CD8 + T cells alone from P8 : F92-106 immune mice decreased the virus titre compared to that in the lungs of control mice (P 0n001) whilst the transfer of CD4 + cells had a lesser effect (Fig. 7b) .
Discussion
An optimal vaccine against RSV should include determinants for the induction of CD8 + CTL. It has been demonstrated in a number of viral infections that CD8 + , MHC class I-restricted CTL are essential for the elimination of virus, and that the absence of these cells leads to a chronic or persistent infection. For example, CD8 + T cells are responsible for the clearance of lymphocytic choriomeningitis virus (LCMV) and are the most dominant anti-viral response in this infection (Moskophidis et al., 1987 ; Fung-Leung et al., 1991) . In RSV infection, CTL can be demonstrated within the lungs of BALB\c mice following i.n. infection (Taylor et al., 1985) , mainly directed against the F protein with some recognizing the nucleoprotein (N) but not the G or the small hydrophobic protein, 1A (Pemberton et al., 1987) . CD8 + T cell responses have additionally been shown to play an important role in the prevention of immunopathology associated with TH2-type responses through the release of IFN-γ. The F protein of RSV was selected as a likely candidate in this study because high levels of F-specific killing can be detected in both mice and humans. In addition, levels of F-specific CTL activity are correlated with recent RSV infection in humans while in mice immunization with purified F protein significantly inhibits virus replication.
The lymphocytes used to screen for peptide-specific CTL responses were isolated from the lungs of mice during primary RSV infection. This is a useful approach because it allows the investigation of effector cells that have differentiated in vivo in response to the virus and migrated back into the tissue. The recognition of P8 : F92-106 by these CTL indicates that this peptide must be processed and presented naturally during RSV infection resulting in CTL proliferation and differentiation. The high levels of killing suggest it is likely to be an important epitope in these animals. Although P8 : F92-106-specific CD4 + and CD8 + T cells were isolated from the lungs, the blocking studies suggest that the main CTL activity was contained within the CD8 + subset. The decreased CTL activity seen following blocking with anti-CD4 antibody may have been a non-specific effect although further studies would be needed to confirm this. CTL that are CD4 + and MHC class II restricted have been described in a number of viral infections but these are usually only detected after culture in vitro, and are not detected if cells are assayed directly during acute infections (Enssle & Fleischer, 1990) . In RSV infection, spleen cells from mice infected with live RSV and restimulated for only one cycle in vitro have CD8 + CTL but repeated re-stimulation in vitro leads to the generation and outgrowth of CD4 + CTL (Nicholas et al., 1990) .
Immunization with P8 : F92-106 alone resulted in CTL responses against both whole RSV and peptide-pulsed cells, confirming that P8 : F92-106 is processed and presented by infected cells. The CTL from immunized mice were again found to be CD8 + and these were able to reduce viral load in the lungs following RSV challenge. Immunization with a single CTL epitope has previously been shown to induce protection against viral infection or tumour growth (Feltkamp et al., 1993 ; Blaney et al., 1998) . In some instances, protective responses were only induced following immunization with the CTL epitope linked to a T helper epitope or other carrier (Partidos et al., 1996) . The differentiation of CTL from P8 : F92-106-immunized mice and the induction of P8 : F92-106-specific proliferative responses following in vitro restimulation strongly suggests that although the peptide does not contain a motif for binding to either MHC class I or class II, it does have epitopes for the generation of both CTL activity and T cell help. This dual function of the peptide makes it particularly interesting.
It is known that MHC class I molecules are capable of binding several different peptides. These peptides are generally 8-9 amino acids long and both N and C termini are bound by hydrogen bonds to conserved residues in the class I peptide binding cleft. In addition, two side-chains, one at the C terminus (usually position 9) and the other at the amino terminus (usually position 2), hold the peptide in allele-specific pockets (Falk et al., 1990 (Falk et al., , 1991 . Using this information for a class I allelic product, it is possible to predict CTL epitopes from a protein sequence. A comparison of the sequence of peptide P8 (ELQLLMQSTPPTNNR) with the published H-2K d anchor motif (1 X 345678Xh, where X l Y, F ; Xh l I, L) shows that this peptide is motif negative and reliance on motif prediction would have missed this epitope. There are several examples in the literature of other motif-negative CTL epitopes (Kast et al., 1993 (Kast et al., , 1994 . Interestingly, peptide P7, with the sequence ELDKYKNAVTELQLL, has an appropriate H-2 d anchor motif but did not prime targets for lysis by RSV-specific CTL.
Peptides presented by MHC class I are produced in the cytosol by the cleavage of partially digested protein antigens by the proteasome enzyme complex. In vivo experiments using purified 20S proteasome have shown that this complex preferentially cuts protein antigens into peptides of either 8-9 EDG amino acids, the usual size of MHC class I epitopes, or 14-15 amino acids, the length of P8 : F92-106 (Niedermann et al., 1996) . An alternative explanation is that P8 : F92-106 was broken down into smaller fragments ( 9-mers) by protease\s that can only cleave the 15-mer sequence. This is unlikely, given that lactacystin had no effect on CTL recognition of P8 : F92-106-pulsed targets. The observation that the use of a protease inhibitor cocktail (including lysosomal protease inhibitors) actually enhanced CTL recognition suggests that P8 : F92-106 is not cleaved and loaded onto MHC class I by an alternative lysosomal pathway as has been shown for some measles virus fusion protein epitopes. Minimal CTL epitopes of up to13 amino acids have been reported (Urban et al., 1994) . Since the MHC class I binding groove is closed at both ends and can only accommodate 8-10 amino acids in a linear form, it is considered that longer peptide epitopes are accommodated by the formation of a central loop or kink in the sequence (Fremont et al., 1992 ; Gromme et al., 1999) or even by zigzagging (Madden et al., 1993) . It has also been suggested that longer peptides can be accommodated by a protrusion mechanism (Stryhn et al., 2000) . Other work has shown that the binding of longer peptides is restricted to peptides extended at their C terminus (Horig et al., 1999) . The demonstration that P8 : F92-106 can promote the in vitro folding of K d heavy chain and β # -microglobulin suggests that the peptide is indeed specific for K d .
Immunization with the 15-mer peptide P8 : F92-106 from the F protein of RSV results in the production of peptide-and virus-specific CTL and peptide-specific proliferative responses. Viral loads in the lungs of RSV-challenged, P8 : F92-106-immunized mice were reduced compared to controls. Viral loads in BALB\c scid mice receiving passively transferred purified CD8 + lymphocytes from P8 : F92-106-immunized mice were reduced compared to controls and these data suggest that P8 : F92-106 had induced protective CD8 + responses. It thus seems possible that appropriately designed epitopespecific peptide vaccines could be considered for use against RSV.
This work was supported by a grant from Action Research U.K.
